Previous 10 | Next 10 |
Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors PR Newswire MARLBOROUGH, Mass. , Jan. 6, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO) to...
Phio Pharmaceuticals press release ( NASDAQ: PHIO ): Q3 GAAP EPS of -$0.26. At September 30, 2022, the Company had cash of $14.5 million as compared with $24.1 million at December 31, 2021. For further details see: Phio Pharmaceuticals GAAP EPS of -$0.26
Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update PR Newswire New executive team leading development of Phio's RNAi compounds and proprietary INTASYL™ platform Continuing enro...
Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th PR Newswire Phio's INTASYL™ compounds demonstrated activity against multiple protein targets including PD-1, BRD4,...
Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) PR Newswire MARLBOROUGH, Mass. , Oct. 6, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage bi...
Clinical stage biotechnology company Phio Pharmaceuticals ( NASDAQ: PHIO ) appointed Robert Bitterman interim executive chairman. Bitterman has served as a director since 2012. Also, Robert Ferrara, chairman of the audit committee, is appointed lead...
Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman PR Newswire MARLBOROUGH, Mass. , Sept. 29, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next ge...
Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference PR Newswire MARLBOROUGH, Mass. , Sept. 22, 2022 /PRN...
Phio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) PR Newswire MARLBOROUGH, Mass. , Sept. 12, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage bio...
Phio Pharmaceuticals press release ( NASDAQ: PHIO ): Q2 GAAP EPS of -$0.19 beats by $0.12 . At June 30, 2022, the Company had cash of $18.0 million as compared with $24.1 million at December 31, 2021. The Company expects its current cash will be sufficient to fund ...
News, Short Squeeze, Breakout and More Instantly...
Phio Pharmaceuticals Corp. Company Name:
PHIO Stock Symbol:
NASDAQ Market:
Phio Pharmaceuticals Corp. Website:
Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells...
Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to ...
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced i...